{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:41:37Z","timestamp":1787316097117,"version":"build-2736575974"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["NO. 82070400"],"award-info":[{"award-number":["NO. 82070400"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100016179","name":"Instituto Nacional de Ci\u00eancia e Tecnologia em Biodiversidade e Produtos Naturais","doi-asserted-by":"publisher","award":["NO. 82270367"],"award-info":[{"award-number":["NO. 82270367"]}],"id":[{"id":"10.13039\/501100016179","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block inhibitors of T cell activation and function. With the widespread use of ICIs in cancer therapy, immune-related adverse events (irAEs) have gradually emerged as urgent clinical issues. Tumors not only\u00a0exhibit high heterogeneity, and their response to ICIs varies, with \u201chot\u201d tumors showing better anti-tumor effects but also a higher susceptibility to irAEs. The manifestation of irAEs displays a tumor-heterogeneous pattern, correlating with the tumor type in terms of the affected organs, incidence, median onset time, and severity. Understanding the mechanisms underlying the pathogenic patterns of irAEs can provide novel insights into the prevention and management of irAEs, guide the development of biomarkers, and contribute to a deeper understanding of the toxicological characteristics of ICIs. In this review, we explore the impact of tumor type on the therapeutic efficacy of ICIs and further elucidate how these tumor types influence the occurrence of irAEs. Finally, we assess key candidate biomarkers and their relevance to proposed irAE mechanisms. This paper also outlines management strategies for patients with various types of tumors, based on their disease patterns.<\/jats:p>","DOI":"10.1007\/s12094-024-03798-6","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T03:48:33Z","timestamp":1735530513000},"page":"3247-3260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of tumor types in immune-related adverse events"],"prefix":"10.1007","volume":"27","author":[{"given":"Qian","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4357-9780","authenticated-orcid":false,"given":"Zhaohui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"3798_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0770-2","volume":"7","author":"S Chen","year":"2019","unstructured":"Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, Pan F, Topalian SL. Mechanisms regulating pd-l1 expression on tumor and immune cells. J Immunother Cancer. 2019;7:1\u201312.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3798_CR2","first-page":"5399","volume":"18","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Fang Y-C, Li J. Pd-l1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett. 2019;18(5):5399\u2013407.","journal-title":"Oncol Lett"},{"issue":"1","key":"3798_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with pd-1\/pd-l1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"issue":"1","key":"3798_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B. Regulatory mechanisms of pd-1\/pd-l1 in cancers. Mol Cancer. 2024;23(1):108.","journal-title":"Mol Cancer"},{"issue":"4","key":"3798_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450\u201361.","journal-title":"Cancer Cell"},{"key":"3798_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"34","author":"SH Baumeister","year":"2016","unstructured":"Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539\u201373.","journal-title":"Annu Rev Immunol"},{"issue":"7637","key":"3798_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"7","key":"3798_CR8","doi-asserted-by":"publisher","first-page":"e002850","DOI":"10.1136\/jitc-2021-002850","volume":"9","author":"BA Siddiqui","year":"2021","unstructured":"Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, et al. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer. 2021;9(7):e002850.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"3798_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"3798_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"26","key":"3798_CR11","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"03","key":"3798_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J De Filette","year":"2019","unstructured":"De Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019;51(03):145\u201356.","journal-title":"Horm Metab Res"},{"issue":"2","key":"3798_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173\u201382.","journal-title":"JAMA Oncol"},{"issue":"10","key":"3798_CR14","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Chen TW-W, Siu L, Hansen AR. Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377\u201385.","journal-title":"Ann Oncol"},{"issue":"6","key":"3798_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.clml.2021.01.010","volume":"21","author":"QJ Gesiotto","year":"2021","unstructured":"Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuyk Endall AT, Song J, Talati C, Sweet K, Lancet JE, et al. Evaluating predictors of immune-related adverse events and response to checkpoint inhibitors in myeloid malignancies. Clin Lymphoma Myeloma Leuk. 2021;21(6):421\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3798_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ceb.2020.01.005","volume":"63","author":"JJ Bianchi","year":"2020","unstructured":"Bianchi JJ, Zhao X, Mays JC, Davoli T. Not all cancers are created equal: tissue specificity in cancer genes and pathways. Curr Opin Cell Biol. 2020;63:135\u201343.","journal-title":"Curr Opin Cell Biol"},{"issue":"3","key":"3798_CR17","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/ijms24032288","volume":"24","author":"MA Al-Hamaly","year":"2023","unstructured":"Al-Hamaly MA, Turner LT, Rivera-Martinez A, Rodriguez A, Blackburn JS. Zebrafish cancer avatars: a translational platform for analyzing tumor heterogeneity and predicting patient outcomes. Int J Mol Sci. 2023;24(3):2288.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3798_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","volume":"23","author":"D Cella","year":"2022","unstructured":"Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, et al. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in checkmate 9er: an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(2):292\u2013303.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3798_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Y-K Kang","year":"2022","unstructured":"Kang Y-K, Chen L-T, Ryu M-H, Oh D-Y, Oh SC, Chung HC, Lee K-W, Omori T, Shitara K, Sakuramoto S, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with her2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (attraction-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"24","key":"3798_CR20","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodr\u0131guez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous nsclc. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"issue":"34","key":"3798_CR21","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud AI, Wolchok JD, Robert C, Hwu W-J, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al. Programmed death-ligand 1 expression and response to the anti\u2013programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34(34):4102\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3798_CR22","doi-asserted-by":"publisher","first-page":"e002852","DOI":"10.1136\/jitc-2021-002852","volume":"9","author":"T Nakamura","year":"2021","unstructured":"Nakamura T, Sato T, Endo R, Sasaki S, Takahashi N, Sato Y, Hyodo M, Hayakawa Y, Harashima H. Sting agonist loaded lipid nanoparticles overcome anti-pd-1 resistance in melanoma lung metastasis via nk cell activation. J Immunother Cancer. 2021;9(7):e002852.","journal-title":"J Immunother Cancer"},{"key":"3798_CR23","doi-asserted-by":"publisher","first-page":"107870","DOI":"10.1016\/j.intimp.2021.107870","volume":"98","author":"M Jalili-Nik","year":"2021","unstructured":"Jalili-Nik M, Soltani A, Mashkani B, Rafatpanah H, Hashemy SI. Pd-1 and pd-l1 inhibitors foster the progression of adult t-cell leukemia\/lymphoma. Int Immunopharmacol. 2021;98:107870.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"3798_CR24","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41417-022-00446-5","volume":"29","author":"H Zuo","year":"2022","unstructured":"Zuo H, Wan Y. Inhibition of myeloid pd-l1 suppresses osteoclastogenesis and cancer bone metastasis. Cancer Gene Ther. 2022;29(10):1342\u201354.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"3798_CR25","doi-asserted-by":"publisher","first-page":"12710","DOI":"10.1111\/aji.12710","volume":"78","author":"L-L Wang","year":"2017","unstructured":"Wang L-L, Li Z-H, Hu X-H, Muyayalo KP, Zhang Y-H, Liao A-H. The roles of the pd-1\/pd-l1 pathway at immunologically privileged sites. Am J Reprod Immunol. 2017;78(2):12710.","journal-title":"Am J Reprod Immunol"},{"issue":"5","key":"3798_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer F, Gulijk M, Mulder EE, Lukkes M, Klaase L, Bosch T, Nimwegen M, Lau SP, Latupeirissa K, Schetters S, et al. The pd-1\/pd-l1-checkpoint restrains t cell immunity in tumor-draining lymph nodes. Cancer Cell. 2020;38(5):685\u2013700.","journal-title":"Cancer Cell"},{"issue":"68","key":"3798_CR27","doi-asserted-by":"publisher","first-page":"112584","DOI":"10.18632\/oncotarget.22576","volume":"8","author":"M Weber","year":"2017","unstructured":"Weber M, Wehrhan F, Baran C, Agaimy A, Buttner-Herold M, Preidl R, Neukam FW, Ries J. Pd-l1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. Oncotarget. 2017;8(68):112584.","journal-title":"Oncotarget"},{"issue":"9","key":"3798_CR28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, Arance A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma (keynote-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239\u201351.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3798_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","volume":"7","author":"W Gao","year":"2022","unstructured":"Gao W, Wang X, Zhou Y, Wang X, Yu Y. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther. 2022;7(1):196.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"3798_CR30","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.apsb.2021.03.027","volume":"11","author":"Q Xie","year":"2021","unstructured":"Xie Q, Ding J, Chen Y. Role of cd8+ t lymphocyte cells: interplay with stromal cells in tumor microenvironment. Acta Pharmaceutica Sinica B. 2021;11(6):1365\u201378.","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"11","key":"3798_CR31","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337.","journal-title":"Nat Med"},{"issue":"8","key":"3798_CR32","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865\u201374.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3798_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"issue":"7528","key":"3798_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-pd-l1 antibody mpdl3280a in cancer patients. Nature. 2014;515(7528):563\u20137.","journal-title":"Nature"},{"issue":"1","key":"3798_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17\u201335.","journal-title":"Immunity"},{"issue":"11","key":"3798_CR36","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"Y-T Liu","year":"2021","unstructured":"Liu Y-T, Sun Z-J. Turning cold tumors into hot tumors by improving t-cell infiltration. Theranostics. 2021;11(11):5365.","journal-title":"Theranostics"},{"issue":"24","key":"3798_CR37","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.1002\/cncr.33780","volume":"127","author":"CC Foster","year":"2021","unstructured":"Foster CC, Couey MA, Kochanny SE, Khattri A, Acharya RK, Tan Y-HC, Brisson RJ, Leidner RS, Seiwert TY. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer. 2021;127(24):4565\u201373.","journal-title":"Cancer"},{"key":"3798_CR38","doi-asserted-by":"publisher","first-page":"703893","DOI":"10.3389\/fonc.2021.703893","volume":"11","author":"L Daniello","year":"2021","unstructured":"Daniello L, Elshiaty M, Bozorgmehr F, Kuon J, Kazdal D, Schindler H, Shah R, Volckmar A-L, Lusky F, Diekmann L, et al. Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer. Front Oncol. 2021;11:703893.","journal-title":"Front Oncol"},{"key":"3798_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07508-7","volume":"20","author":"C-E Wu","year":"2020","unstructured":"Wu C-E, Yang C-K, Peng M-T, Huang P-W, Chang C-F, Yeh K-Y, Chen C-B, Wang C-L, Hsu C-W, Chen I-W, et al. The association between immune-related adverse events and survival outcomes in asian patients with advanced melanoma receiving anti-pd-1 antibodies. BMC Cancer. 2020;20:1\u201312.","journal-title":"BMC Cancer"},{"issue":"10","key":"3798_CR40","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/onco.13868","volume":"26","author":"DJ Martini","year":"2021","unstructured":"Martini DJ, Goyal S, Liu Y, Evans ST, Olsen TA, Case K, Magod BL, Brown JT, Yantorni L, Russler GA, et al. Immune-related adverse events as clinical biomarkers in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist. 2021;26(10):1742\u201350.","journal-title":"Oncologist"},{"issue":"2","key":"3798_CR41","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","volume":"50","author":"M Delaunay","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot J-M, Raimbourg J, Girard N, Guisier F, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50(2):1700050.","journal-title":"Eur Respir J"},{"key":"3798_CR42","doi-asserted-by":"publisher","first-page":"1104888","DOI":"10.3389\/fonc.2023.1104888","volume":"13","author":"L Luo","year":"2023","unstructured":"Luo L, Liu Y, Lu J, Zhang Y, Fan G, Tang X, Guo W. Risk factors for cardiovascular adverse events from immune checkpoint inhibitors. Front Oncol. 2023;13:1104888.","journal-title":"Front Oncol"},{"key":"3798_CR43","doi-asserted-by":"publisher","first-page":"236060","DOI":"10.3389\/fimmu.2016.00613","volume":"7","author":"MC Hunter","year":"2016","unstructured":"Hunter MC, Teijeira A, Halin C. T cell trafficking through lymphatic vessels. Front Immunol. 2016;7:236060.","journal-title":"Front Immunol"},{"issue":"10","key":"3798_CR44","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014\u201322.","journal-title":"Nat Immunol"},{"issue":"12","key":"3798_CR45","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"J-E Salem","year":"2018","unstructured":"Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano J-P, Balko JM, Bonaca MP, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"12","key":"3798_CR46","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","volume":"125","author":"O Oren","year":"2020","unstructured":"Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors. Am J Cardiol. 2020;125(12):1920\u20136.","journal-title":"Am J Cardiol"},{"issue":"1","key":"3798_CR47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41698-021-00223-x","volume":"5","author":"F Wang","year":"2021","unstructured":"Wang F, Yang S, Palmer N, Fox K, Kohane IS, Liao KP, Yu K-H, Kou S. Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types. NPJ Precis Oncol. 2021;5(1):82.","journal-title":"NPJ Precis Oncol"},{"issue":"7","key":"3798_CR48","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Aguilera JV, Chintakuntlawar A, et al. Treatment-related adverse events of pd-1 and pd-l1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008\u201319.","journal-title":"JAMA Oncol"},{"key":"3798_CR49","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022;13:779691.","journal-title":"Front Immunol"},{"issue":"12","key":"3798_CR50","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor\u2013related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607\u201316.","journal-title":"JAMA Oncol"},{"key":"3798_CR51","doi-asserted-by":"publisher","first-page":"749064","DOI":"10.3389\/fonc.2021.749064","volume":"11","author":"ML Bastacky","year":"2021","unstructured":"Bastacky ML, Wang H, Fortman D, Rahman Z, Mascara GP, Brenner T, Najjar YG, Luke JJ, Kirkwood JM, Zarour HM, et al. Immune-related adverse events in pd-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis. Front Oncol. 2021;11:749064.","journal-title":"Front Oncol"},{"key":"3798_CR52","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","volume":"145","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2019;145:479\u201385.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"3798_CR53","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","volume":"17","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020;17(8):504\u201315.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"3798_CR54","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","volume":"5","author":"F Berner","year":"2019","unstructured":"Berner F, Bomze D, Diem S, Ali OH, Fassler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, et al. Association of checkpoint inhibitor\u2013induced toxic effects with shared cancer and tissue antigens in non\u2013small cell lung cancer. JAMA Oncol. 2019;5(7):1043\u20137.","journal-title":"JAMA Oncol"},{"issue":"75","key":"3798_CR55","doi-asserted-by":"publisher","first-page":"9644","DOI":"10.1126\/sciimmunol.abn9644","volume":"7","author":"F Berner","year":"2022","unstructured":"Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann LK, Marcu A, et al. Autoreactive napsin a\u2013specific t cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol. 2022;7(75):9644.","journal-title":"Sci Immunol"},{"issue":"1","key":"3798_CR56","doi-asserted-by":"publisher","first-page":"2006893","DOI":"10.1080\/2162402X.2021.2006893","volume":"10","author":"F Berner","year":"2021","unstructured":"Berner F, Niederer R, Luimstra JJ, Pop OT, Jochum A-K, Purde M-T, Hasan Ali O, Bomze D, Bauer J, Freudenmann LK, et al. Keratinocyte differentiation antigen-specific t cells in immune checkpoint inhibitor-treated nsclc patients are associated with improved survival. Oncoimmunology. 2021;10(1):2006893.","journal-title":"Oncoimmunology"},{"issue":"2","key":"3798_CR57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.medj.2022.12.007","volume":"4","author":"NG Nunez","year":"2023","unstructured":"Nunez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde M-T, Niederer R, Porsch M, Lichtensteiger C, et al. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med. 2023;4(2):113\u201329.","journal-title":"Med"},{"issue":"2","key":"3798_CR58","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"1","key":"3798_CR59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suarez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Prim. 2020;6(1):38.","journal-title":"Nat Rev Dis Prim"},{"issue":"11","key":"3798_CR60","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1001\/jamaoncol.2019.3221","volume":"5","author":"D Bomze","year":"2019","unstructured":"Bomze D, Ali OH, Bate A, Flatz L. Association between immune-related adverse events during anti\u2013pd-1 therapy and tumor mutational burden. JAMA Oncol. 2019;5(11):1633\u20135.","journal-title":"JAMA Oncol"},{"issue":"3","key":"3798_CR61","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3798_CR62","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jamaoncol.2019.3158","volume":"5","author":"DA Braun","year":"2019","unstructured":"Braun DA, Ishii Y, Walsh AM, Van Allen EM, Wu CJ, Shukla SA, Choueiri TK. Clinical validation of pbrm1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma. JAMA Oncol. 2019;5(11):1631\u20133.","journal-title":"JAMA Oncol"},{"key":"3798_CR63","doi-asserted-by":"publisher","first-page":"633032","DOI":"10.3389\/fonc.2021.633032","volume":"11","author":"Y Fan","year":"2021","unstructured":"Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, Hao Y, Zhang Z. Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis. Front Oncol. 2021;11:633032.","journal-title":"Front Oncol"},{"issue":"4","key":"3798_CR64","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886\u201394.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3798_CR65","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, et al. Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer. JAMA Oncol. 2018;4(3):374\u20138.","journal-title":"JAMA Oncol"},{"key":"3798_CR66","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Vareki SM, Fernandes R. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2013a systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3798_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","volume":"43","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, Cabiddu M, Ghilardi M, Borgonovo K, Parati MC, et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother. 2020;43(1):1\u20137.","journal-title":"J Immunother"},{"key":"3798_CR68","doi-asserted-by":"publisher","first-page":"570752","DOI":"10.3389\/fonc.2020.570752","volume":"10","author":"LM Rose","year":"2021","unstructured":"Rose LM, DeBerg HA, Vishnu P, Frankel JK, Manjunath AB, Flo-res JPE, Aboulafia DM. Incidence of skin and respiratory immune-related adverse events correlates with specific tumor types in patients treated with checkpoint inhibitors. Front Oncol. 2021;10:570752.","journal-title":"Front Oncol"},{"issue":"3","key":"3798_CR69","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","volume":"82","author":"C Nardin","year":"2020","unstructured":"Nardin C, Jeand\u2019Heur A, Bouiller K, Valnet-Rabier MB, Dresco F, Castagna J, Mareschal A, Carlet C, Nerich V, Limat S, et al. Vitiligo under anti\u2013programmed cell death-1 therapy is associated with increased survival in melanoma patients. J Am Acad Dermatol. 2020;82(3):770\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3798_CR70","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345\u201361.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"3798_CR71","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/imr.13258","volume":"318","author":"F Berner","year":"2023","unstructured":"Berner F, Flatz L. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: a focus on autoimmune skin toxicity and pneumonitis. Immunol Rev. 2023;318(1):37\u201350.","journal-title":"Immunol Rev"},{"issue":"18","key":"3798_CR72","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"key":"3798_CR73","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3389\/fphar.2019.01350","volume":"10","author":"Y-W Zhou","year":"2019","unstructured":"Zhou Y-W, Zhu Y-J, Wang M-N, Xie Y, Chen C-Y, Zhang T, Xia F, Ding Z-Y, Liu J-Y. Immune checkpoint inhibitor-associated cardiotoxicity: current understanding on its mechanism, diagnosis and management. Front Pharmacol. 2019;10:1350.","journal-title":"Front Pharmacol"},{"issue":"7937","key":"3798_CR74","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, et al. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7937):818\u201326.","journal-title":"Nature"},{"issue":"6","key":"3798_CR75","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","volume":"41","author":"T Won","year":"2022","unstructured":"Won T, Kalinoski HM, Wood MK, Hughes DM, Jaime CM, Del-gado P, Talor MV, Lasrado N, Reddy J, Cihakova D. Cardiac myosin-specific autoimmune t cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 2022;41(6):111611.","journal-title":"Cell Rep"},{"issue":"1","key":"3798_CR76","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1346-8138.14074","volume":"45","author":"H Sueki","year":"2018","unstructured":"Sueki H, Mizukawa Y, Aoyama Y. Immune reconstitution inflammatory syndrome in non-hiv immunosuppressed patients. J Dermatol. 2018;45(1):3\u20139.","journal-title":"J Dermatol"},{"issue":"4","key":"3798_CR77","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559\u201374.","journal-title":"Ann Oncol"},{"issue":"7","key":"3798_CR78","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11912-023-01414-4","volume":"25","author":"LI Yousif","year":"2023","unstructured":"Yousif LI, Screever EM, Versluis D, Aboumsallem JP, Nierkens S, Man-intveld OC, Boer RA, Meijers WC. Risk factors for immune checkpoint inhibitor\u2013mediated cardiovascular toxicities. Curr Oncol Rep. 2023;25(7):753\u201363.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"3798_CR79","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.xcrm.2022.100878","volume":"4","author":"MA Huseni","year":"2023","unstructured":"Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, Liu L-F, Li Y, Gupta V, Li C, et al. Cd8+ t cell-intrinsic il-6 signaling promotes resistance to anti-pd-l1 immunotherapy. Cell Rep Med. 2023;4(1):100878.","journal-title":"Cell Rep Med"},{"key":"3798_CR80","doi-asserted-by":"publisher","first-page":"570233","DOI":"10.3389\/fonc.2020.570233","volume":"10","author":"F Barron","year":"2020","unstructured":"Barron F, Sanchez R, Arroyo-Hernandez M, Blanco C, Zatarain-Barron ZL, Catalan R, Ramos-Ram\u0131rez M, Cardona AF, Flores-Estrada D, Arri-eta O. Risk of developing checkpoint immune pneumonitis and its effect on overall survival in non-small cell lung cancer patients previously treated with radiotherapy. Front Oncol. 2020;10:570233.","journal-title":"Front Oncol"},{"issue":"7","key":"3798_CR81","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1759-7714.12759","volume":"9","author":"O Kanai","year":"2018","unstructured":"Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, Yoshida H, Akai M, Mio T, Hirai T. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thoracic cancer. 2018;9(7):847\u201355.","journal-title":"Thoracic cancer"},{"key":"3798_CR82","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","volume":"69","author":"R Shibaki","year":"2020","unstructured":"Shibaki R, Murakami S, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Kusumoto M, et al. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunother. 2020;69:15\u201322.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3798_CR83","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12890-022-02127-3","volume":"22","author":"X Li","year":"2022","unstructured":"Li X, Lv F, Wang Y, Du Z. Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia. BMC Pulm Med. 2022;22(1):331.","journal-title":"BMC Pulm Med"},{"issue":"11","key":"3798_CR84","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1159\/000526141","volume":"101","author":"P Zhou","year":"2022","unstructured":"Zhou P, Zhao X, Wang G. Risk factors for immune checkpoint inhibitor-related pneumonitis in cancer patients: a systemic review and meta-analysis. Respiration. 2022;101(11):1035\u201350.","journal-title":"Respiration"},{"key":"3798_CR85","doi-asserted-by":"publisher","first-page":"698832","DOI":"10.3389\/fonc.2021.698832","volume":"11","author":"X Lin","year":"2021","unstructured":"Lin X, Deng H, Yang Y, Wu J, Qiu G, Li S, Xie X, Liu M, Xie Z, Qin Y, et al. Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer. Front Oncol. 2021;11:698832.","journal-title":"Front Oncol"},{"issue":"5","key":"3798_CR86","doi-asserted-by":"publisher","first-page":"268","DOI":"10.14740\/jocmr4511","volume":"13","author":"A Manne","year":"2021","unstructured":"Manne A, Mulekar MS, Escobar DE, Alsayed A, Sharma G, Proddu-turvar P, Howard JH, Gilbert R, Alkharabsheh O, et al. Clinical and hematological predictors of high-grade immune-related adverse events associated with immune checkpoint inhibitors. J Clin Med Res. 2021;13(5):268.","journal-title":"J Clin Med Res"},{"key":"3798_CR87","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.lungcan.2019.02.011","volume":"130","author":"Y Sakata","year":"2019","unstructured":"Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y, Anan K, Hisanaga J, Nitawaki T, Iio M, et al. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment. Lung Cancer. 2019;130:159\u201361.","journal-title":"Lung Cancer"},{"issue":"2","key":"3798_CR88","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.cell.2016.03.001","volume":"165","author":"L Zitvogel","year":"2016","unstructured":"Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and anticancer immunosurveillance. Cell. 2016;165(2):276\u201387.","journal-title":"Cell"},{"key":"3798_CR89","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.coi.2018.12.003","volume":"56","author":"F Chen","year":"2019","unstructured":"Chen F, Stappenbeck TS. Microbiome control of innate reactivity. Curr Opin Immunol. 2019;56:107\u201313.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"3798_CR90","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368\u201379.","journal-title":"Ann Oncol"},{"issue":"12","key":"3798_CR91","doi-asserted-by":"publisher","first-page":"e003334","DOI":"10.1136\/jitc-2021-003334","volume":"9","author":"J Mao","year":"2021","unstructured":"Mao J, Wang D, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, et al. Gut microbiome is associated with the clinical response to anti-pd-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. 2021;9(12):e003334.","journal-title":"J Immunother Cancer"},{"key":"3798_CR92","doi-asserted-by":"publisher","first-page":"1266850","DOI":"10.3389\/fimmu.2024.1266850","volume":"15","author":"M-X Lin","year":"2024","unstructured":"Lin M-X, Zang D, Liu C-G, Han X, Chen J. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management. Front Immunol. 2024;15:1266850.","journal-title":"Front Immunol"},{"key":"3798_CR93","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00262-021-02855-1","volume":"70","author":"K Tyan","year":"2021","unstructured":"Tyan K, Baginska J, Brainard M, Giobbie-Hurder A, Severgnini M, Manos M, Haq R, Buchbinder EI, Ott PA, Hodi FS, et al. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 2021;70:2209\u201321.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3798_CR94","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.rdc.2024.01.004","volume":"50","author":"W Bracamonte-Baran","year":"2024","unstructured":"Bracamonte-Baran W, Kim ST. The current and future of biomarkers of immune related adverse events. Rheum Dis Clin. 2024;50(2):201\u201327.","journal-title":"Rheum Dis Clin"},{"issue":"1","key":"3798_CR95","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s40168-022-01373-1","volume":"10","author":"MZ Islam","year":"2022","unstructured":"Islam MZ, Tran M, Xu T, Tierney BT, Patel C, Kostic AD. Reproducible and opposing gut microbiome signatures distinguish autoimmune diseases and cancers: a systematic review and meta-analysis. Microbiome. 2022;10(1):218.","journal-title":"Microbiome"},{"issue":"11","key":"3798_CR96","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/art.39783","volume":"68","author":"Y Maeda","year":"2016","unstructured":"Maeda Y, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K, Hirota K, Matsushita M, Furuta Y, Narazaki M, et al. Dysbiosis contributes to arthritis development via activation of autoreactive t cells in the intestine. Arthritis Rheumatol. 2016;68(11):2646\u201361.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"3798_CR97","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.40359","volume":"70","author":"J Manasson","year":"2018","unstructured":"Manasson J, Shen N, Garcia Ferrer HR, Ubeda C, Iraheta I, Heguy A, Von Feldt JM, Espinoza LR, Garcia Kutzbach A, Segal LN, et al. Gut microbiota perturbations in reactive arthritis and postinfectious spondyloarthritis. Arthritis Rheumatol. 2018;70(2):242\u201354.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"3798_CR98","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/microbiolspec.GPP3-0045-2018","volume":"7","author":"MW Cunningham","year":"2019","unstructured":"Cunningham MW. Molecular mimicry, autoimmunity, and infection: the cross-reactive antigens of group a streptococci and their sequelae. Microbiol Spectr. 2019;7(4):10\u20131128.","journal-title":"Microbiol Spectr"},{"issue":"4","key":"3798_CR99","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/imm.12950","volume":"154","author":"KL Flannigan","year":"2018","unstructured":"Flannigan KL, Denning TL. Segmented filamentous bacteria-induced immune responses: a balancing act between host protection and autoimmunity. Immunology. 2018;154(4):537\u201346.","journal-title":"Immunology"},{"issue":"5","key":"3798_CR100","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/imt-2018-0144","volume":"11","author":"T Liu","year":"2019","unstructured":"Liu T, Xiong Q, Li L, Hu Y. Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea. Immunotherapy. 2019;11(5):385\u201396.","journal-title":"Immunotherapy"},{"issue":"12","key":"3798_CR101","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1111\/1759-7714.13990","volume":"12","author":"B Tan","year":"2021","unstructured":"Tan B, Chen M-J, Guo Q, Tang H, Li Y, Jia X-M, Xu Y, Zhu L, Wang M-Z, Qian J-M. Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events. Thoracic Cancer. 2021;12(12):1814\u201323.","journal-title":"Thoracic Cancer"},{"key":"3798_CR102","doi-asserted-by":"publisher","first-page":"756872","DOI":"10.3389\/fimmu.2021.756872","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu W, Ma F, Sun B, Liu Y, Tang H, Luo J, Chen H, Luo Z. Intestinal microbiome associated with immune-related adverse events for patients treated with anti-pd-1 inhibitors, a real-world study. Front Immunol. 2021;12:756872.","journal-title":"Front Immunol"},{"key":"3798_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-01002-w","volume":"23","author":"F Pirozzi","year":"2021","unstructured":"Pirozzi F, Poto R, Aran L, Cuomo A, Galdiero MR, Spadaro G, Abete P, Bonaduce D, Marone G, Tocchetti CG, et al. Cardiovascular toxicity of immune checkpoint inhibitors: clinical risk factors. Curr Oncol Rep. 2021;23:1\u20138.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"3798_CR104","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000498985","volume":"12","author":"N Agrawal","year":"2019","unstructured":"Agrawal N, Khunger A, Vachhani P, Colvin TA, Hattoum A, Spangen-thal E, Curtis AB, Dy GK, Ernstoff MS, Puzanov I. Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature. Case Rep Oncol. 2019;12(1):260\u201376.","journal-title":"Case Rep Oncol"},{"issue":"5","key":"3798_CR105","first-page":"350","volume":"33","author":"B Mladosievicova","year":"2020","unstructured":"Mladosievicova B, Orszaghova Z Jr, Jablonicka M, Reckova M, Chovanec M, Mego M. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors. Klinicka Onkologie Casopis Ceske a Slovenske Onkologicke Spolecnosti. 2020;33(5):350\u20135.","journal-title":"Klinicka Onkologie Casopis Ceske a Slovenske Onkologicke Spolecnosti"},{"key":"3798_CR106","doi-asserted-by":"publisher","first-page":"882167","DOI":"10.3389\/fcvm.2022.882167","volume":"9","author":"X Chen","year":"2022","unstructured":"Chen X, Jiang A, Zhang R, Fu X, Liu N, Shi C, Wang J, Zheng X, Tian T, Liang X, et al. Immune checkpoint inhibitor-associated cardiotoxi-city in solid tumors: real-world incidence, risk factors, and prognostic analysis. Front Cardiovasc Med. 2022;9:882167.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"3798_CR107","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NM, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):447\u201358.","journal-title":"Lancet Oncol"},{"issue":"16","key":"3798_CR108","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinz-erling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"3798_CR109","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2217\/pgs-2022-0113","volume":"23","author":"C Udagawa","year":"2022","unstructured":"Udagawa C, Nakano MH, Yoshida T, Ohe Y, Kato K, Mushiroda T, Zembutsu H. Association between genetic variants and the risk of nivolumab-induced immune-related adverse events. Pharmacogenomics. 2022;23(16):887\u2013901.","journal-title":"Pharmacogenomics"},{"issue":"18","key":"3798_CR110","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-21-0921","volume":"27","author":"J Luo","year":"2021","unstructured":"Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, Rizvi H, Egger JV, Plodkowski AJ, Abu-Akeel M, et al. Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with pd-1 blockade in non\u2013small cell lung cancer. Clin Cancer Res. 2021;27(18):5131\u201340.","journal-title":"Clin Cancer Res"},{"key":"3798_CR111","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s00262-020-02797-0","volume":"70","author":"N Abdel-Wahab","year":"2021","unstructured":"Abdel-Wahab N, Diab A, Yu RK, Futreal A, Criswell LA, Tayar JH, Dadu R, Shannon V, Shete SS, Suarez-Almazor ME. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 2021;70:1939\u201349.","journal-title":"Cancer Immunol Immunother"},{"key":"3798_CR112","doi-asserted-by":"publisher","first-page":"216998","DOI":"10.1016\/j.canlet.2024.216998","volume":"596","author":"YJ Kim","year":"2024","unstructured":"Kim YJ, Lee M, Kim EH, Lee S, Park S, Hong MH, Shin SJ, Jung I, Lee C-K, Lee CS. Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: a nationwide retrospective cohort study. Cancer Lett. 2024;596:216998.","journal-title":"Cancer Lett"},{"key":"3798_CR113","doi-asserted-by":"publisher","first-page":"102751","DOI":"10.1016\/j.ctrv.2024.102751","volume":"127","author":"L Rached","year":"2024","unstructured":"Rached L, Laparra A, Sakkal M, Danlos F-X, Barlesi F, Carbonnel F, De Martin E, Ducreux M, Even C, Le Pavec J, et al. Toxicity of immunotherapy combinations with chemotherapy across tumor indications: current knowledge and practical recommendations. Cancer Treat Rev. 2024;127:102751.","journal-title":"Cancer Treat Rev"},{"key":"3798_CR114","doi-asserted-by":"publisher","first-page":"112142","DOI":"10.1016\/j.intimp.2024.112142","volume":"133","author":"W Liu","year":"2024","unstructured":"Liu W, Xiao C, Luo J, Liu M, Sun B, Luo Z. Unveiling the role of fto polymorphisms in predicting response to immune checkpoint inhibitors: a retrospective study. Int Immunopharmacol. 2024;133:112142.","journal-title":"Int Immunopharmacol"},{"key":"3798_CR115","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejca.2023.01.034","volume":"184","author":"Z Xin","year":"2023","unstructured":"Xin Z, You L, Na F, Li J, Chen M, Song J, Bai L, Chen J, Zhou J, Ying B. Immunogenetic variations predict immune-related adverse events for pd-1\/pd-l1 inhibitors. Eur J Cancer. 2023;184:124\u201336.","journal-title":"Eur J Cancer"},{"key":"3798_CR116","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785.","journal-title":"J Clin Oncol"},{"key":"3798_CR117","doi-asserted-by":"publisher","first-page":"952099","DOI":"10.3389\/fimmu.2022.952099","volume":"13","author":"N Jiang","year":"2022","unstructured":"Jiang N, Yu Y, Zhang M, Tang Y, Wu D, Wang S, Fang Y, Zhang Y, Meng L, Li Y, et al. Association between germ-line hla and immune-related adverse events. Front Immunol. 2022;13:952099.","journal-title":"Front Immunol"},{"issue":"7","key":"3798_CR118","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, et al. Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3798_CR119","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3747\/co.25.4047","volume":"25","author":"A Kartolo","year":"2018","unstructured":"Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM. Predictors of immunotherapy-induced immune-related adverse events. Curr Oncol. 2018;25(5):403\u201310.","journal-title":"Curr Oncol"},{"issue":"6","key":"3798_CR120","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-line immunotherapy for non\u2013small-cell lung cancer. J Clin Oncol. 2022;40(6):586\u201397.","journal-title":"J Clin Oncol"},{"key":"3798_CR121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.1003","author":"P Schmid","year":"2019","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Henschel V, Molinero L, Chui SY, et al. IMpassion130:updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo)+ nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). Am Soc Clin Oncol. 2019. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.1003.","journal-title":"Am Soc Clin Oncol"},{"key":"3798_CR122","doi-asserted-by":"publisher","first-page":"6000","DOI":"10.1200\/JCO.2019.37.15_suppl.6000","volume":"37","author":"D Rischin","year":"2019","unstructured":"Rischin D, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro G, Psyrri A, Baste N, Neupane PC, Bratland A, et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC). Am Soc Clin Oncol. 2019;37:6000.","journal-title":"Am Soc Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03798-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:14:16Z","timestamp":1757135656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03798-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":122,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["3798"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03798-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is neither financial support nor other benefits from commercial sources to be reported for the work presented in the manuscript, nor any other financial interests that any of the authors may have, which could create a potential conflict of interest or the appearance of a conflict of interest concerning the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any research involving human participants or animals conducted by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}}]}}